Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia type 2 (MEN2), Neurofibromatosis type 1 (NF1), Von Hippel-Lindau syndrome (V, HL), and Tuberous sclerosis complex (TSC) illness have all increased the incidence and frequency of neuroendocrine tumors in the United States. Furthermore, according to research published in the JAMA Oncology journal, the survival rate for all neuroendocrine tumor treatments has improved, particularly for distant-stage gastrointestinal and pancreatic neuroendocrine tumor treatments.
This is mostly due to improved results as a result of the availability of better treatments and earlier diagnosis. The launch of novel treatments and expanded indications for established medications would assist the growth of the neuroendocrine tumor therapy market in North America, which would in turn substantially boost the worldwide market. In terms of income, the United States is the largest market for NET. There is no definite date for the occurrence of neuroendocrine tumors in Canada. According to the Canadian Cancer Society, 315 individuals in Canada were diagnosed with endocrine malignancies in 2012, and the prevalence is rising due to early detection and stage migration.
Throughout the projected period, the neuroendocrine tumor therapy market in North America is likely to dominate the worldwide gastrointestinal NET sector. According to Coherent Market Insights, several national institutions and small pharma companies are working on creating NET medicines and changing the therapeutic approach to treating neuroendocrine tumors. This provides pharma and biotech firms with a significant chance to promote their goods in the United States.